SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed.
The chemical structure of SC-4289 is the same as for methallenestril but differs in that it is the benzyl ether and not the methyl ether.
SC-4289 makes an appearance in the allenestrol patent, as well as a stand-alone compound in: